Topline results from two Phase III clinical trials indicate that ritlecitinib demonstrated promising efficacy in patients with active or stable nonsegmental vitiligo (NSV). These positive Phase III findings support the potential expansion of ritlecitinib as an oral treatment option for nonsegmental vitiligo, pending detailed data presentation and regulatory review. “The positive results from the TRANQUILLO pivotal studies in nonsegmental vitiligo build on our deep expertise in dermatology and on our experience with LITFULO in severe alopecia areata, including its established efficacy and well-characterized safety profile. “Living with nonsegmental vitiligo can have a profound impact on patients’ daily lives. Additional results from TRANQUILLO and TRANQUILLO 2 will be presented at a future medical meeting.